Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?
Gillian Murphy and Hideaki Nagase*
Correspondence *Department of Matrix Biology, The Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College London, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK
Email h.nagase@imperial.ac.uk
Metalloproteinases are thought to be involved in the pathological destruction of joint tissues in rheumatoid arthritis and osteoarthritis; however, matrix metalloproteinase inhibitors failed to effectively treat disease in early clinical trials. It is now clear that more-specific inhibition of these enzymes is required for the success of this therapeutic approach.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Pathogenesis of arthritis: recent research progressNature Immunology News and Views (01 Sep 2001)
RESEARCH
ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitroNature Letters to Editor (31 Mar 2005)
See all 39 matches for Research